Kessen Patten

3x2patten-kessen

Working Group Member

Professor - Centre Armand-Frappier Santé Biotechnologie

Institut National de la Recherche Scientifique (INRS)


NMD4C Involvement: Pillar 1: Preclinical Science, Theme 5: Open Science

Email Kessen

Biography

Dr. Kessen Patten is an Associate Professor at the INRS-Institut Armand Frappier in Canada. He did his PhD in Physiology and Cell Biology at the University of Alberta, followed by two postdoctoral trainings at the Université de Montreal. During his academic training, Dr. Patten has provided new insights in mechanisms of synaptic development using zebrafish, discovered a new gene associated with idiopathic scoliosis and identified neuroleptics as potential therapeutics for amyotrophic lateral sclerosis (ALS), with one compound currently in clinical trial.

 

The Patten lab uses the zebrafish to model developmental genetic disorders and neuromuscular diseases (ALS and SMA) to understand disease mechanisms and for drug discovery. Dr. Patten is the recipient of the ALS Canada and Brain Canada Career transition award as well as a Fonds de recherche du Québec – Santé (FRQS) Junior 2 Research Scholar. He also holds the Anna Sforza Djoukhadjian Research Chair in ALS.


Recent Publications

McDermott, A, Bernier, C, Piché, V, Plante, I, Patten, SA. Exposure to an environmentally representative mixture of polybrominated diphenyl ethers (PBDEs) alters zebrafish neuromuscular development. Neurotoxicology. 2024. PMID:39490620

Lescouzères, L, Patten, SA. Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update. Expert Opin Drug Discov. 2024.19 (10)1213-1233 PMID:39115327

Breuer, M, Rummler, M, Singh, J, Maher, S, Zaouter, C, Jamadagni, P et al.. CHD7 regulates craniofacial cartilage development via controlling HTR2B expression. J Bone Miner Res. 2024.39 (4)498-512 PMID:38477756

Oliveira Silva, R, Counil, H, Rabanel, JM, Haddad, M, Zaouter, C, Ben Khedher, MR et al.. Donepezil-Loaded Nanocarriers for the Treatment of Alzheimer's Disease: Superior Efficacy of Extracellular Vesicles Over Polymeric Nanoparticles. Int J Nanomedicine. 2024.19 1077-1096 PMID:38317848

De Pace, R, Maroofian, R, Paimboeuf, A, Zamani, M, Zaki, MS, Sadeghian, S et al.. Biallelic BORCS8 variants cause an infantile-onset neurodegenerative disorder with altered lysosome dynamics. Brain. 2024.147 (5)1751-1767 PMID:38128568

See more on PubMed